$TYME News Article - TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas
https://marketwirenews.com/news-releases/tyme...31453.html